Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
 to The Nasdaq Stock Market - EconoTimes)
NEW YORK, Oct. 27, 2016 -- Ra Pharmaceuticals Inc. (Nasdaq:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation, visited the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market on October 26, 2016.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d59a5715-0c97-4d3d-a5e3-bb4d47a6045b
Ra Pharmaceuticals uses its proprietary peptide chemistry Extreme Diversity™ platform to develop novel therapeutics for the treatment of diseases that are caused by excessive or uncontrolled activation of the complement system, which is a critical component of the body’s immune system. The Company’s lead compound, RA101495, is a self-administered subcutaneous injection that is entering Phase 2 development for the treatment of paroxysmal nocturnal hemoglobinuria, or PNH, a life-threatening blood disorder.
“Listing on Nasdaq is an important milestone for our Company that we are very proud to have achieved,” said Douglas Treco, Ph.D., Chief Executive Officer and Co-Founder of Ra Pharmaceuticals Inc. “Nasdaq is home to many of the world’s most innovative biotechnology companies, and we are honored to now be among them. We look forward to executing on our clinical strategy in our quest to create novel therapies for patients and value for our shareholders.”
“Ra Pharmaceuticals is developing the next generation of therapies to treat complex autoimmune diseases,” said Nelson Griggs, Executive Vice President, Listing Services, Nasdaq. “As the leading exchange for some of the world’s most successful life sciences companies, we are proud to be the listing partner of Ra Pharmaceuticals as they continue to develop therapies that will improve the lives of people with these serious and sometimes debilitating diseases.”
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.3 trillion and more than 18,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com
- NDAQG -
Media Relations Contacts: Stephanie Lowenthal (646) 441-5073 [email protected] Emily Pan (646) 441-5120 [email protected]
